An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Applied UV Announces $5 Million Secured Revolving Credit Facility
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Applied UV, Inc. (AUVI) announced a secured revolving credit facility of $5 million on December 8, 2022. This facility will support the company’s growth initiatives and has no existing balance. President Max Munn stated that the firm has increased capital availability by $7.5 million recently, enhancing liquidity to meet growing product demand in the hospitality sector. The company focuses on pathogen elimination technologies and has established a strong customer base including major healthcare and commercial organizations.
Positive
Secured $5 million credit facility strengthens liquidity.
Total capital availability increased by $7.5 million.
Funding will support growth initiatives and backlog fulfillment.
Negative
None.
100% Debt Financing with No Equity Component
MOUNT VERNON, N.Y.--(BUSINESS WIRE)--
Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company, announces today a $5 million secured revolving credit facility effective December 8, 2022. Borrowings under the revolving credit facility will be used for general corporate purposes and to advance Applied UV’s organic and strategic growth initiatives. The facility currently has no outstanding balance.
Max Munn, Applied UV, Inc.’s President and Founder, said, “This facility further bolsters our near-term liquidity position and provides us with additional flexibility to execute our growth strategy including the timely delivery of products from an increasing backlog of orders in our hospitality business. Over the past few weeks, we have increased capital availability by $7.5 million with the closing of this new revolver and $2.5 million in an unsecured loan earlier this month. We are taking the steps necessary to ensure we have access to capital to support an acceleration in sales and deliver positive cash flow.”
Additional details regarding the credit facility are available in a Current Report on Form 8-K filed with Securities and Exchange Commission.
About Applied UV
Applied UV, Inc. (“AUVI”) develops and acquires proprietary infection prevention and control technology in the healthcare, commercial & public venue, food processing/storage, cannabis, and education, vertical markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). Sterilumen owns and markets a portfolio of products with advanced pathogen elimination technology, branded Airocide® by Sterilumen, Scientific Air™ by Sterilumen, Airoclean™ 420 by Sterilumen, and Lumicide™ by Sterilumen.
Leading organizations globally rely on AUVI’s air purification systems to completely eliminate airborne and surface infections, mold, bacteria, allergens and other contaminants. Our customers include Kaiser Permanente, NY Health+Hospitals, Baptist Health South Florida, Boston Red Sox’s Fenway Park, JetBlue Park, France’s Palace of Versailles, Invited Clubs, Whole Foods, Del Monte Foods, U.S. Department of Veterans Affairs, and more.
NASA used Airocide’s and Airoclean™ 420’s Photocatalytic Oxidation technology to sanitize its International Space Station.
Scientifically proven to reduce Healthcare Acquired Infections (HAI), Scientific Air™ offers a proprietary 3-stage technology integrating HEPA filters, ultraviolet germicidal light chamber and active carbon substrate.
For information on Applied UV, Inc., and its subsidiaries, please visit the following websites:
The information contained herein may contain “forward‐looking statements.” Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company’s current expectations and assumptions regarding its business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company’s actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.
